Characterization of Treatment Resistant Depression Episodes in a Cohort of Patients from a US Commercial Claims Database

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Kubitz, Nicole ^a   Mehra, Maneesha ^b   Potluri, Ravi C ^c   Garg, Nitesh ^c   Cossrow, Nicole ^b  

^a JANSSEN CILAG GMBH   (Germany)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c SmartAnalyst   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; FEMALE; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESISTANT DEPRESSION; UNITED STATES;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG THERAPY, COMBINATION; EPISODE OF CARE; FEMALE; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); YOUNG ADULT;

EID: 84885736296     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076882     Document Type: Article

References (26)

1. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, et al. (2011) Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 9: 90.
2. OECD Expert Meeting: Mental health, disability and work (2010) Available: http://www.oecd.org/els/45008308.pdf Accessed 2013 Sep 9.
3. Hirschfeld RMA, Weissman MM (2002) Risk Factors For Major Depression And Bipolar Disorder. Neuropsychopharmacology: The Fifth Generation of Progress Section 8: Chapter 70.
4. French L Treatment of Co-morbid Alcohol Use Disorders and Depression, Baylor College of Medicine, Houston, Texas, Available: http://www.bcm.edu/psychiatry/index.cfm?pmid=20058 Accessed 2013 Sep 9.
5. Musselman DL, Evans DL, Nemeroff CB, (1998) The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 55: 580-592.
6. Mezuk B, Eaton WW, Albrecht S, Golden SH, (2008) Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 31: 2383-2390.
7. Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, et al. (2010) Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin 26: 2475-2484.
8. Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ, (2002) Identification of a claims data "signature" and economic consequences for treatment-resistant depression. J Clin Psychiatry 63: 717-726.
9. The Global Burden of Disease (2004), WHO report. Available: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf Accessed 2013 Sep 9.
10. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, et al. (2003) The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 64: 1465-1475.
11. Economic Burden of Mental Illness- A Fact Sheet, Florida Cuncil of Community Mental Health; Available: www.fccmh.org/resources/docs/EconomicBurdenofMentalIllness.pdf Accessed 2013 Sep 9.
12. EMEA-CHMP (2009) Concept Paper On The Need For Revision Of Note For Guidance On Clinical Investigation Of Medicinal Products In The Treatment Of Depression With Regard To Treatment Resistant Depression. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004861.pdf Accessed 2013 Sep 9.
13. Keller MB, (2005) Issues in treatment-resistant depression. J Clin Psychiatry 66Suppl 8: 5-12.
14. Vieta E, Colom F, (2011) Therapeutic options in treatment-resistant depression. Ann Med 43: 512-530.
15. Gibson TB, Jing Y, Smith Carls G, Kim E, Bagalman JE, et al. (2010) Cost burden of treatment resistance in patients with depression. Am J Manag Care 16: 370-377.
16. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, et al. (1999) Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 9: 83-91.
17. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, et al. (2002) The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 63: 963-971.
18. Managing Chronic Depression; Available: http://harvardpartnersinternational.staywellsolutionsonline.com/HealthNewsLetters/69,M1209a Accessed 2013 Sep 9.
19. Antidepressant Medication During Acute Phase for Patients with New Episode of Major Depression: PQRI Measure 9 (2007);Available: http://www.findacode.com/pqri/2007/PQRI%20Measure%209.pdf Accessed 2013 Sep 9.
20. Nemeroff CB, (2007) Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68Suppl 8: 17-25.
21. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, et al. (2009) What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 60: 1439-1445.
22. Philip NS, Carpenter LL, Tyrka AR, Price LH, (2010) Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother 11: 709-722.
23. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition (2010). October, 2010 ed. Available: http://psychiatryonline.org/content.aspx?bookid=28§ionid=1667485 Accessed 2013 Sep 9.
24. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, et al. (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105.
25. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905-1917.
26. Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A, (2004) Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 22: 363-373.